ClinicalTrials.Veeva

Menu

Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients

A

Asan Medical Center

Status

Completed

Conditions

Graft Failure
Chronic Kidney Diseases
Acute Kidney Injury

Study type

Observational

Funder types

Other

Identifiers

NCT06340607
2023-0561

Details and patient eligibility

About

This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Full description

Acute kidney injury (AKI) after liver transplantation (LT) significantly affects patient and graft outcomes. The Albumin-Bilirubin (ALBI) score, an objective and sensitive index of liver function, has potential applicability in predicting outcomes following LT. This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients.

Enrollment

3,422 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • living donor liver transplantation recipients (≥18 years)

Exclusion criteria

  • preoperative serum creatinine (sCr) > 1.4 mg/dL, diagnosed CKD or hepatorenal syndrome (HRS), or hemodialysis at baseline

Trial design

3,422 participants in 2 patient groups

Recipients with neohepatic ALBI ≥ -1.615
Description:
The ALBI score was calculated using the formula: (log10bilirubin × 0.66) + (albumin × -0.085), where bilirubin is measured in μmol/L and albumin in g/L. Recipients with neohepatic (post-reperfusion) ALBI ≥ -1.615
Recipients with neohepatic ALBI < -1.615
Description:
Recipients with neohepatic (post-reperfusion) ALBI \< -1.615

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems